Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib and chemotherapy in CML myeloid blastic phase or Bcr-abl positive AML
NCT01690065Phase 2Unknown
- Sponsor
- Ulsan University Hospital
- Start
- Sep 2012
- Primary completion
- Sep 2019
- Countries
- 1
01
Overview
Phase 2, open-label trial of nilotinib in chronic myeloid leukemia (CML) and acute myeloid leukemia (AML), sponsored by Ulsan University Hospital. Primary endpoint: Complete Remission Rate at 8 weeks. Status: unknown.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01690065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01690065.